Stem Cell Res Ther. 2013;4(6):159. doi: 10.1186/scrt389.
The incidence of type 1 diabetes is increasing worldwide. Current therapy continues to be suboptimal. An exciting therapeutic advance in the short term is closed loop technology development and application. However, cell and tissue therapy continues to be an unmet need for the disorder. Human islets isolated from deceased donors will be clinically available to treat type 1 diabetes within the next 1 to 2 years. Other approaches such as xenotransplantation and islet products derived from human embryonic stem cells and induced pluripotent stem cells are currently being pursued. The current commentary provides context and discusses future endeavors for transplantation of islet-like structures derived from fetal pancreas.
1 型糖尿病的发病率在全球范围内呈上升趋势。目前的治疗方法仍不尽如人意。短期内令人兴奋的治疗进展是闭环技术的开发和应用。然而,细胞和组织治疗仍然是该疾病未满足的需求。从已故供体中分离出的人胰岛将在未来 1 到 2 年内可用于临床治疗 1 型糖尿病。其他方法,如异种移植和源自人类胚胎干细胞和诱导多能干细胞的胰岛产品,目前正在研究中。本评论提供了背景信息,并讨论了来源于胎儿胰腺的胰岛样结构移植的未来努力。